SK Capital Names Senior Management Team for Noramco

From DCAT Value Chain Insights (VCI)

By People On The Move posted 07-26-2016 12:39


SK Capital, a private investment firm, has announced a new organizational structure and additions to the senior management team of the firm’s recently acquired specialty active pharmaceutical ingredient and raw materials businesses, Noramco Inc. and Tasmanian Alkaloids.

Matthew Martin, who was previously the general manager for the recently acquired businesses has been appointed chief executive officer (CEO). Mr. Martin will be supported by a management team comprised of senior executives that are transitioning with the businesses as well as an influx of new talent. The expanded team will be tasked with driving the operational improvements and customer-focused initiatives that are expected to be captured as an independent, carved-out organization as well as from the restructuring of the businesses as two separate entities. Mr. Martin held a variety of roles with increasing responsibility with Johnson & Johnson companies in the UK, Canada, and US. Mr. Martin has held Management Board positions as CFO, CIO, vice president of marketing and business unit leader in companies within both the medical devices and pharmaceutical sectors. In his most recent position, Mr. Martin was the general manager for the acquired businesses. In that role,Mr. Martin was responsible for all commercial, research & development, regulatory affairs, external manufacturing, and project management.

The new additions to the management team and their respective positions are: Jim Mish, president, Noramco; Chris Close, chief financial officer (CFO); and Charlie Enzinger, vice president, integrated supply chain, Noramco.

Jim Mish has spent over 30 years in the specialty chemical industry in executive leadership positions at both privately held and publicly traded companies. He joins the team from Ashland, where he held the role of president of Global Consumer Specialties, a global provider of pharmaceutical, personal care, and nutritional specialty ingredients. Previously, he served as senior vice president of Personal Care and Pharmaceutical Ingredients at International Specialty Products , which was acquired by Ashland in 2011. He began his career at Pfizer Pharmaceutical in research and development before holding positions of increasing responsibility at Imperial Chemical Industries (ICI), ARCO Chemical, Penn Specialty Chemicals, and National Starch.

Chris Close joins from Preferred Proppants where he held the position of CFO. He brings significant financial leadership and experience in chemicals, energy and distribution with a broad based financial background that encompasses FP&A, investor relations, M&A, treasury, financial reporting and accounting. Mr. Close started his career in public accounting with PricewaterhouseCoopers before progressing into industry, where he has operated in both corporate and business unit roles at companies such as ARCO Chemical, Airgas, Exelon Corporation and Constellation Energy.

Doug Blackaby has been the managing director for Tasmanian Alkaloids since 2013. Previously, he was the director, Alkaloid Raw Materials Business for Tasmanian Alkaloids with direct responsibilities for sales and marketing and field operations. He began with Tasmanian Alkaloids as an EHS Manager and later became director, EHS GPSG Asia Pacific, a role that included responsibilities for Johnson & Johnson manufacturing sites in Fuji Japan, Xian China and Korea Gi-Do.

Charlie Enzinger joins the team from Univar, where he was responsible for leading the company’s supply-chain transformation initiatives. Throughout his career, he has held executive roles at leading industrial and specialty chemical companies, including Nalco and DuPont where he specialized in leading turnaround initiatives such as improving underperforming supply chain and plant operations. Mr. Enzinger is trained in Six Sigma, Lean Enterprise and Theory of Constraints.

The existing leaders, who will transition into new roles in the new structure and other key leaders are as follows:
In Noramco, Matthew Martin, CEO; Anthony Ambrosini, CFO, US; Bill Grubb, vice president, commercial; Mat Minardi, general manager, Wilmington; John Daly, director, US CMO & product transfer; Val Coscia, director, US R&D; and Urs Thurnheer, managing director, Noramco GmbH.

In Tasmanian Alkaloids, existing leaders that will will transition into new roles and other key leaders are: Doug Blackaby, managing director; Colin Ralph, general manager; Ian Jones, CFO; Iziar Iriondo, director, quality operations; Sam Bailey, director, scientific affairs; Les Baxter, director, agricultural R&D; and John Kearns, director, logistics and procurement.

Source: SK Capital


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription